These immuno-scores, including TMB (tumor mutational burden), PD-L1, CTLA4, or immune-related genes (HLA-B, HLA-A, HLA-DRA), expand knowledge in tumor immune status and provide a potent prediction tool for the future [28,29]. The gene discussed is HLA-B; the disease is neoplasm.